600222 太龙药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.7012.766-4.4700.3852.070
总资产报酬率 ROA (%)0.7411.213-1.9540.1670.925
投入资产回报率 ROIC (%)1.0521.775-2.5040.1890.973

边际利润分析
销售毛利率 (%)28.15427.28224.07728.86026.454
营业利润率 (%)2.3562.134-3.6102.2192.328
息税前利润/营业总收入 (%)5.4054.662-0.9845.7016.837
净利润/营业总收入 (%)2.8072.166-3.8640.4221.947

收益指标分析
经营活动净收益/利润总额(%)59.14179.25640.946909.53084.702
价值变动净收益/利润总额(%)7.848-14.95213.385-87.46324.101
营业外收支净额/利润总额(%)-0.380-2.80314.568-377.957-12.823

偿债能力分析
流动比率 (X)1.0701.2081.1771.1781.252
速动比率 (X)0.8100.9320.9160.9471.020
资产负债率 (%)55.66154.61455.24853.01954.842
带息债务/全部投入资本 (%)37.10030.32733.42139.474--
股东权益/带息债务 (%)159.607213.566190.278127.520106.550
股东权益/负债合计 (%)77.27080.80578.81482.77278.190
利息保障倍数 (X)1.7671.803-0.3041.0891.432

营运能力分析
应收账款周转天数 (天)150.815126.000112.925113.1660.000
存货周转天数 (天)128.545108.344100.644115.1150.000